Ixazomib: First Global Approval

Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis

(2015) Neeraj Gupta et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients

(2015) Neeraj Gupta et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Implications of Oral Proteasome Inhibition: Impact on Patients

(2015) S. Kumar   Clinical Lymphoma Myeloma & Leukemia

Safety Profile of Oral Ixazomib: Experience from 761 Patients (Pts) Across 14 Phase 1 or Phase 1/2 Clinical Studies

(2015) S. Lonial et al.   Clinical Lymphoma Myeloma & Leukemia

Oral therapy for multiple myeloma: ixazomib arriving soon

(2014) P. Moreau   BLOOD

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

(2014) S. K. Kumar et al.   BLOOD

Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

(2014) A. Garcia-Gomez et al.   CLINICAL CANCER RESEARCH

MLL/KMT2Atranslocations in diffuse large B-cell lymphomas

(2014) Tatyana Gindin et al.   HEMATOLOGICAL ONCOLOGY

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

(2011) E. C. Lee et al.   CLINICAL CANCER RESEARCH

In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

(2011) Dharminder Chauhan et al.   CLINICAL CANCER RESEARCH

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH